AC Immune to Present at AD/PD™ 2025, Showcasing Advances in Active Immunotherapies for Neurodegenerative Diseases
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company specializing in precision therapeutics to combat neurodegenerative diseases, has announced its participation in the upcoming International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025) scheduled to take place in Vienna, Austria, from April 1 to April 5, 2025.
As part of its involvement, AC Immune is set to host an industry symposium on April 2, highlighting its advancements in active immunotherapies directed at preventing neurodegenerative diseases. The symposium is aimed at uncovering tailored prevention strategies that leverage specific immunotherapeutic approaches, a topic critical to expanding the understanding and treatment of diseases like Alzheimer's and Parkinson's.
The symposium will commence at 8:40 am CET in Hall A, opening with remarks from AC Immune’s CEO, Andrea Pfeifer, Ph.D., who emphasized the need for innovative prevention strategies. "Unlocking active immunotherapy for tailored prevention strategies in neurodegenerative diseases," she stated, setting the stage for a detailed exploration of recent findings.
Among the topics to be discussed are critical presentations focusing on perspectives of disease modification in Parkinson's disease, and developments in targeting alpha-synuclein, a significant protein involved in the pathology of these conditions.
Among those presenting are:
- Werner Poewe, M.D. (Medical University of Innsbruck), who will present on "Perspectives of disease-modification in Parkinson’s disease" from 8:50 to 9:10 am CET.
- Günther Staffler, Ph.D. (AC Immune), discussing "Targeting alpha-synuclein in early Parkinson’s disease: ACI-7104.056 in the Phase 2 trial VacSYn" at 9:10 am CET.
- Philip Scheltens, M.D., Ph.D. (EQT Life Sciences, Amsterdam University Medical Center), with a presentation on "Precision Prevention for Alzheimer’s disease" at 9:25 am CET.
- Lennert Steukers, Ph.D. (Johnson & Johnson Innovative Medicine), who will share insights on "The first active immunotherapy for AD prevention: ACI-35.030/JNJ2056 in the Phase 2b Retain study" at 9:50 am CET.
- Anke Post, M.D., Ph.D. (AC Immune), presenting on "Anti-Abeta active immunotherapy in early AD and DSAD: ACI-24.060 in the Phase 1b/2 ABATE study" at 10:05 am CET.
These presentations will not only highlight emerging therapies in development but also address clinical challenges and the evolving landscape of neurodegenerative disease treatment.
Attendees will have the opportunity to engage in a Q&A session following the main presentations, a platform for discussing the practical implications of these findings in the therapeutic arena. Replays of the symposium will be available on AC Immune’s website after the event, allowing for ongoing engagement with the data presented.
In addition to the symposium, AC Immune will also feature oral presentations on innovative drugs such as Morphomer® small molecules targeting Tau, a protein implicated in Alzheimer’s pathology. Presentation slots include:
- Nicolas Preitner, Ph.D. (AC Immune) on "Morphomer® small molecules targeting Tau for the treatment of Alzheimer’s disease" on April 5 at 16:40 pm CET in Hall C.
- Nampally Sreenivasachary, Ph.D. (AC Immune), who will present a virtual on-demand session today covering "Development of Morphomer-antibody drug conjugates – a new class of drugs for neurodegenerative diseases".
- Elpida Tsika, Ph.D. (AC Immune), focusing on "Discovery and optimization of therapeutic small molecules targeting alpha-synuclein aggregation."
With an extensive research pipeline, AC Immune is not just presenting its findings but also solidifying its role as a pioneering force in the fight against neurodegenerative diseases. The company boasts a robust financial footing, with over $4.5 billion in potential milestone payments from collaborations with significant pharmaceutical partners.
As the conference approaches, the anticipation builds within the scientific community for the insights that AC Immune and other participants will share. This conference presents a unique opportunity to delve deeper into the latest scientific advancements, furthering the collective understanding of neurodegenerative disease management and prevention.
In conclusion, with the continuous challenges posed by diseases like Alzheimer’s and Parkinson’s, the advancements being made in active immunotherapies present a hopeful pathway for patients and families affected by these conditions. AC Immune is at the forefront, making significant strides that could lead to groundbreaking changes in treatment approaches.
